Novostia

Novostia is a Swiss medical device company founded in 2017, located in Epalinges near Lausanne. The company specializes in developing an innovative artificial heart valve, particularly aimed at young patients, including children. Novostia operates within the Biopôle life sciences community, fostering collaboration with leading research and innovation groups. The flagship product, the Triflo valve, is designed to improve the quality of life for patients suffering from aortic and mitral valve diseases. It features lifelong durability, low thrombogenicity to minimize blood clot risks, and a low acoustic signature for quiet operation. The valve has shown promising results in laboratory and animal studies and is preparing for first-in-human clinical trials. Novostia's primary customers include healthcare providers such as hospitals and specialized cardiac centers, as well as patients needing heart valve replacements. The company aims to enhance patient outcomes and reduce healthcare costs by offering a valve that does not require lifelong anticoagulation therapy.

• Employees15
• Founded2017
• Annual Revenue$2000000
• Total Funding$19726952